In recent years, several somatic mutations, such as FLT3 and NPM1, were shown to be strongly prognostic and have been incorporated into risk categories of AML in both NCCN guidelines and ELN recommendations2,3. This evidence concerns the gene FLT3 and acute myeloid leukemia.